No headlines found.
Anteris Technologies Global Corp. Announces Closing of $88.8 Million U.S. Initial Public Offering
Business Wire (Mon, 16-Dec 7:49 PM ET)
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.
Anteris Technologies Global Corp. trades on the NASDAQ stock market under the symbol AVR.
As of January 17, 2025, AVR stock price declined to $5.99 with 47,496 million shares trading.
AVR has a market cap of $215.28 million. This is considered a Small Cap stock.
AVR support price is $5.76 and resistance is $6.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVR shares will trade within this expected range on the day.